Thyroidectomy for Graves' Disease or Amiodarone-induced Thyrotoxicosis
NCT ID: NCT06963203
Last Updated: 2025-07-02
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
486 participants
Study Classification
OBSERVATIONAL
Study Start Date
2025-07-01
Study Completion Date
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this observational study is to learn about the potential differences in morbidity of thyroidectomy (removal of the thyroid gland) depending on the preoperative hormonal status. The main question it aims to answer is:
Do patients undergoing thyroidectomy for thyreotoxicosis (thyroid hyperfunction) due to Graves' disease or Amiodarone induced thyreotoxicosis have comparable complication rates depending on their thyroid metabolic status prior or during the procedure.
The data from participants undergoing a thyroidectomy at one of the study sites will be prospectively registered in the EUROCRINE registry, including an add-on module for additional study specific routine data. The operation itself, the preoperative or postoperative treatments are not altered in any way.
Do patients undergoing thyroidectomy for thyreotoxicosis (thyroid hyperfunction) due to Graves' disease or Amiodarone induced thyreotoxicosis have comparable complication rates depending on their thyroid metabolic status prior or during the procedure.
The data from participants undergoing a thyroidectomy at one of the study sites will be prospectively registered in the EUROCRINE registry, including an add-on module for additional study specific routine data. The operation itself, the preoperative or postoperative treatments are not altered in any way.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy
NCT03066076
Graves Disease
Graves Ophthalmopathy
Graves' Ophthalmopathy Worsened
UNKNOWN
PHASE3
Subtotal Versus Total Thyroidectomy for Graves' Disease
NCT01408368
Thyroid
Goiter
COMPLETED
NA
The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy
NCT01056419
Graves' Ophthalmopathy
UNKNOWN
PHASE4
Total Versus Subtotal Thyroidectomy in Graves' Disease At AUH
NCT04577664
Thyroid Goiter
UNKNOWN
NA
Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance
NCT01295333
Graves Disease (Basedow's Disease)
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
Thyrotoxicosis is the clinical condition associated with excessive thyroid hormone activity, usually due to inappropriately high levels of circulating thyroid hormones. The clinical presentation is variable, ranging from asymptomatic to life-threatening 'thyroid storm'. Symptoms include weight loss, heat intolerance and palpitations. Thyrotoxicosis can result from diffuse alterations of the thyroid gland, such as Graves' disease and Amiodarone-induced thyrotoxicosis (AIT). This poses a considerable challenge across multiple medical specialties, spanning endocrinology, cardiology, and anesthesiology.
Graves' disease is a widespread endocrine disorder that affects approximately 1% of the population. Treatment strategies vary based on clinical presentation and patient preferences, with options ranging from medical management to thyroidectomy. Amiodarone is a class III antiarrhythmic drug used to treat supraventricular and ventricular arrhythmias, and to maintain sinus rhythms after cardioversion of atrial fibrillation. Its prescription has become more common in recent decades. However, the medication comes with the risk of precipitating severe thyrotoxicosis, which, if left untreated, can be fatal. Discontinuing the medication may not always be feasible.
Under medical treatment for thyrotoxicosis (using thionamides or glucocorticoids), attaining euthyroidism can frequently be challenging to achieve, prompting consideration of definitive treatment through thyroidectomy.
Thyroidectomy for Graves' disease or AIT presents unique disease-specific challenges, potentially resulting in elevated perioperative complication rates when compared to other indications. According to current guidelines, it is recommended to attain a euthyroid state prior to surgery to mitigate perioperative risks, despite the inconclusive evidence supporting this approach. Nevertheless, data from retrospective studies show that between 21-51% of patients undergo surgery when euthyroidism is not stable or cannot be achieved.
The EUROCRINE® registry offers a valuable opportunity to assess the morbidity linked to thyroidectomy for Graves' disease and AIT, considering both euthyroid and hyperthyroid states. This prospective, observational study aims to refine surgical protocols and inform updates to existing guidelines, thereby advancing the management of thyroidectomy for Graves' disease and AIT.
Objectives:
The aim of this study is to explore potential differences in the morbidity of thyroidectomy for Graves' disease and AIT based on thyroid metabolic status prior to or during the procedure. The study hypothesis is that there will be no significant differences in relevant complication rates, such as transient and permanent nerve palsy, transient and permanent hypoparathyroidism, reoperation, severe adverse intraoperative cardiac events, or the onset of a "thyroid storm".
If this hypothesis is confirmed, patients with Graves' disease and AIT who are scheduled for thyroidectomy would no longer need to wait to reach a state of euthyroidism. This would streamline preoperative assessments and expedite surgical planning, leading to reduced costs and shorter waiting times, and minimizing exposure to dangerous and excessive levels of thyroxine.
The primary endpoint is the relevant complication rate in both groups: transient and permanent nerve palsy, transient and permanent hypoparathyroidism, reoperation for postoperative haemorrhage, and occurrence of a "thyroid storm".
The secondary endpoints are results of other complications, duration of surgery, estimated blood loss, intraoperative tachycardia, length of hospital stay, ICU monitoring, preoperative medications, use of autofluorescence, angiofluorescence, and neuromonitoring, preoperative calcium and/or vitamin D supplementation, clinic volume.
Design:
The investigatiors are planning a prospective, observational, multicenter, multinational study based on the EUROCRINE® registry. Eurocrine® is an international endocrine surgical quality registry based in the EU. The project will be a Swiss national and multinational multicenter study.
Several other in Eurocrine® participating, international clinics have agreed to participate in the study. It is planned that a total of around 25 clinics in various European countries will take part in the study. In a first step, the participating centers in Switzerland will be opened.
The data will be entered prospectively into the online registry in encrypted form, which is the standard for the Eurocrine® registry. For the Eurocrine® registry itself a declaration of no objection has been issued in May 2017 for Switzerland (2017-00683). The clinics participating in the study do this part of the data entry unchanged from before. The participant can then be enrolled in the study via a my-Eurocrine add-on module and additional study-specific routine data can be collected directly in the Registry online platform. All variables, along with the study- specific variables, are systematically collected in the centers as a component of patient care, since these parameters are essential for treatment. The operation itself, the preoperative or postoperative treatments are not altered in any way. Information about postoperative complications will be registered at the Eurocrine® database as previously implemented.
Patients with Graves' disease or AIT can be included in this study and will be assigned to two groups. The investigators rely on free triiodothyronine (fT3) and free thyroxine (fT4) levels to assess functional status since the TSH level may not accurately reflect the patient's true functional status. Patients will be classified as uncontrolled if their levels of fT3 or fT4 are elevated, or as controlled (normal fT3 and fT4) immediately prior to surgery (normal ranges for all ages: fT4 12.0 - 22.0 pmol/l; fT3 3.1 - 6.8 pmol/l). The fT3 and fT4 tests will be conducted no more than one week before surgery. Consecutive patient enrolment is necessary to accurately reflect real clinical conditions. The standard variables are recorded as usual, with the addition of the study-specific variables (see CRF). All complications will be documented to evaluate the risk of surgery in both controlled and uncontrolled metabolic states.
For diagnosing patients with "thyroid storm", the investigators opted to utilize the established Japanese Association classification, which is deemed more suitable for clinical settings compared to the "Burch and Wartofsky" scale.
Origin of the data:
The investigators want to analyze data routinely collected in the clinical practice for adult, non- pregnant patients who underwent surgical management of Graves ' disease and AIT in different functional states. The variables are summarized in the CRF.
All data will be collected in the Eurocrine database with the standard module and an add-on specific variable my-Eurocrine module for study specific routine data. All participating sites will use the Eurocrine database and collect their data prospectively online and in a coded form. In the Eurocrine data registry, data is routinely recorded up to six months postoperatively in the event of complications occurring during treatment. This period also corresponds to that of the study project.
It is planned to run the study for 2 years and the study will start as soon as a positive ethical decision has been made. If enough patients have been enrolled before the end of the 2 years, the study will be stopped early.
Information and consent of participants:
The investigators will collect and analyze data routinely collected in clinical practice. The consent procedure at all Swiss sites are as followed:
Patients are informed through the documents entitled \<General consent for the re-use of health-related data and samples for research purposes.\>. All study patients provide approved informed consent for the further use of their medical records and tissue samples using the general document from the Hospital.
For clinics that do not have general consent, the Eurocrine consent form is used as standard (German and English versions available).
If a patient does not agree to the General Consent of the Swiss sites using the General Consent, but agrees to the use of data related to the thyroid disease and treatment, the patient can be enrolled in the study by signing the Eurocrine Consent.
Thyrotoxicosis is the clinical condition associated with excessive thyroid hormone activity, usually due to inappropriately high levels of circulating thyroid hormones. The clinical presentation is variable, ranging from asymptomatic to life-threatening 'thyroid storm'. Symptoms include weight loss, heat intolerance and palpitations. Thyrotoxicosis can result from diffuse alterations of the thyroid gland, such as Graves' disease and Amiodarone-induced thyrotoxicosis (AIT). This poses a considerable challenge across multiple medical specialties, spanning endocrinology, cardiology, and anesthesiology.
Graves' disease is a widespread endocrine disorder that affects approximately 1% of the population. Treatment strategies vary based on clinical presentation and patient preferences, with options ranging from medical management to thyroidectomy. Amiodarone is a class III antiarrhythmic drug used to treat supraventricular and ventricular arrhythmias, and to maintain sinus rhythms after cardioversion of atrial fibrillation. Its prescription has become more common in recent decades. However, the medication comes with the risk of precipitating severe thyrotoxicosis, which, if left untreated, can be fatal. Discontinuing the medication may not always be feasible.
Under medical treatment for thyrotoxicosis (using thionamides or glucocorticoids), attaining euthyroidism can frequently be challenging to achieve, prompting consideration of definitive treatment through thyroidectomy.
Thyroidectomy for Graves' disease or AIT presents unique disease-specific challenges, potentially resulting in elevated perioperative complication rates when compared to other indications. According to current guidelines, it is recommended to attain a euthyroid state prior to surgery to mitigate perioperative risks, despite the inconclusive evidence supporting this approach. Nevertheless, data from retrospective studies show that between 21-51% of patients undergo surgery when euthyroidism is not stable or cannot be achieved.
The EUROCRINE® registry offers a valuable opportunity to assess the morbidity linked to thyroidectomy for Graves' disease and AIT, considering both euthyroid and hyperthyroid states. This prospective, observational study aims to refine surgical protocols and inform updates to existing guidelines, thereby advancing the management of thyroidectomy for Graves' disease and AIT.
Objectives:
The aim of this study is to explore potential differences in the morbidity of thyroidectomy for Graves' disease and AIT based on thyroid metabolic status prior to or during the procedure. The study hypothesis is that there will be no significant differences in relevant complication rates, such as transient and permanent nerve palsy, transient and permanent hypoparathyroidism, reoperation, severe adverse intraoperative cardiac events, or the onset of a "thyroid storm".
If this hypothesis is confirmed, patients with Graves' disease and AIT who are scheduled for thyroidectomy would no longer need to wait to reach a state of euthyroidism. This would streamline preoperative assessments and expedite surgical planning, leading to reduced costs and shorter waiting times, and minimizing exposure to dangerous and excessive levels of thyroxine.
The primary endpoint is the relevant complication rate in both groups: transient and permanent nerve palsy, transient and permanent hypoparathyroidism, reoperation for postoperative haemorrhage, and occurrence of a "thyroid storm".
The secondary endpoints are results of other complications, duration of surgery, estimated blood loss, intraoperative tachycardia, length of hospital stay, ICU monitoring, preoperative medications, use of autofluorescence, angiofluorescence, and neuromonitoring, preoperative calcium and/or vitamin D supplementation, clinic volume.
Design:
The investigatiors are planning a prospective, observational, multicenter, multinational study based on the EUROCRINE® registry. Eurocrine® is an international endocrine surgical quality registry based in the EU. The project will be a Swiss national and multinational multicenter study.
Several other in Eurocrine® participating, international clinics have agreed to participate in the study. It is planned that a total of around 25 clinics in various European countries will take part in the study. In a first step, the participating centers in Switzerland will be opened.
The data will be entered prospectively into the online registry in encrypted form, which is the standard for the Eurocrine® registry. For the Eurocrine® registry itself a declaration of no objection has been issued in May 2017 for Switzerland (2017-00683). The clinics participating in the study do this part of the data entry unchanged from before. The participant can then be enrolled in the study via a my-Eurocrine add-on module and additional study-specific routine data can be collected directly in the Registry online platform. All variables, along with the study- specific variables, are systematically collected in the centers as a component of patient care, since these parameters are essential for treatment. The operation itself, the preoperative or postoperative treatments are not altered in any way. Information about postoperative complications will be registered at the Eurocrine® database as previously implemented.
Patients with Graves' disease or AIT can be included in this study and will be assigned to two groups. The investigators rely on free triiodothyronine (fT3) and free thyroxine (fT4) levels to assess functional status since the TSH level may not accurately reflect the patient's true functional status. Patients will be classified as uncontrolled if their levels of fT3 or fT4 are elevated, or as controlled (normal fT3 and fT4) immediately prior to surgery (normal ranges for all ages: fT4 12.0 - 22.0 pmol/l; fT3 3.1 - 6.8 pmol/l). The fT3 and fT4 tests will be conducted no more than one week before surgery. Consecutive patient enrolment is necessary to accurately reflect real clinical conditions. The standard variables are recorded as usual, with the addition of the study-specific variables (see CRF). All complications will be documented to evaluate the risk of surgery in both controlled and uncontrolled metabolic states.
For diagnosing patients with "thyroid storm", the investigators opted to utilize the established Japanese Association classification, which is deemed more suitable for clinical settings compared to the "Burch and Wartofsky" scale.
Origin of the data:
The investigators want to analyze data routinely collected in the clinical practice for adult, non- pregnant patients who underwent surgical management of Graves ' disease and AIT in different functional states. The variables are summarized in the CRF.
All data will be collected in the Eurocrine database with the standard module and an add-on specific variable my-Eurocrine module for study specific routine data. All participating sites will use the Eurocrine database and collect their data prospectively online and in a coded form. In the Eurocrine data registry, data is routinely recorded up to six months postoperatively in the event of complications occurring during treatment. This period also corresponds to that of the study project.
It is planned to run the study for 2 years and the study will start as soon as a positive ethical decision has been made. If enough patients have been enrolled before the end of the 2 years, the study will be stopped early.
Information and consent of participants:
The investigators will collect and analyze data routinely collected in clinical practice. The consent procedure at all Swiss sites are as followed:
Patients are informed through the documents entitled \<General consent for the re-use of health-related data and samples for research purposes.\>. All study patients provide approved informed consent for the further use of their medical records and tissue samples using the general document from the Hospital.
For clinics that do not have general consent, the Eurocrine consent form is used as standard (German and English versions available).
If a patient does not agree to the General Consent of the Swiss sites using the General Consent, but agrees to the use of data related to the thyroid disease and treatment, the patient can be enrolled in the study by signing the Eurocrine Consent.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Graves Disease
Amiodarone-Induced Thyrotoxicosis
Thyroidectomy
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CONTROL
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
euthyreoid
Patients undergoing thyroidectomy in a euthyreoid state.
No interventions assigned to this group
non-euthyreoid
Patients undegoing thyroidectomy in a non-euthyreoid state.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult patients (≥ 18 years of age) undergoing surgical treatment for Graves' disease or Amiodarone-induced thyrotoxicosis (AIT) with biochemically confirmed hyperthyroidism or on specific medication for the treatment of Graves' disease or AIT.
* Patients providing signed informed consent.
* Patients providing signed informed consent.
Exclusion Criteria
* Children and minors (\<18 years).
* Pregnant women.
* Patients unable or unwilling to provide informed consent due to language barriers or intellectual limitations.
* Patients undergoing concurrent parathyroidectomy for primary or secondary hyperparathyroidism, lymph node clearance, or redo surgery.
* Surgical procedures performed for other reasons than Graves' disease or AIT
* Pregnant women.
* Patients unable or unwilling to provide informed consent due to language barriers or intellectual limitations.
* Patients undergoing concurrent parathyroidectomy for primary or secondary hyperparathyroidism, lymph node clearance, or redo surgery.
* Surgical procedures performed for other reasons than Graves' disease or AIT
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Spital Männedorf
UNKNOWN
Sponsor Role
collaborator
Spital Limmattal Schlieren
OTHER
Sponsor Role
collaborator
Centre Hospitalier Universitaire Vaudois
OTHER
Sponsor Role
collaborator
Ospedale Regionale di Mendrisio
OTHER
Sponsor Role
collaborator
Kantonsspital St. Gallen, Switzerland
UNKNOWN
Sponsor Role
collaborator
Cantonal Hosptal, Baselland
OTHER
Sponsor Role
collaborator
St. Claraspital AG
OTHER
Sponsor Role
collaborator
University Hospital, Geneva
OTHER
Sponsor Role
collaborator
Insel Gruppe AG, University Hospital Bern
OTHER
Sponsor Role
collaborator
ASZ Aalst
OTHER
Sponsor Role
collaborator
University Hospital Virgen de las Nieves
OTHER
Sponsor Role
collaborator
University of Nancy
OTHER
Sponsor Role
collaborator
Hospital Costa del Sol
OTHER
Sponsor Role
collaborator
Evgenidion Hospital Athens, Greece
UNKNOWN
Sponsor Role
collaborator
Andrea Goldmann
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrea Goldmann
Fellow of the European Board of Surgery (FEBS) - Endocrine Surgery, Schwerpunkt Viszeralchirurgie, FMH Chirurgie, Kantonsspital Winterthur Klinik für Viszeral- und Thoraxchirurgie Stv. Chefärztin und Stv. Klinikleiterin, Teamleiterin Endokrine Chirurgie
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrea Goldmann, MD
Role: PRINCIPAL_INVESTIGATOR
Kantonsspital Winterthur KSW
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
OLV Ziekenhuis
Aalst, , Belgium
Site Status
RECRUITING
Universite de Lorraine, Cru Nancy
Nancy, , France
Site Status
RECRUITING
Evgenidion Hospital Athens
Athens, , Greece
Site Status
RECRUITING
Universitario Virgen de las Nieves
Granada, , Spain
Site Status
RECRUITING
Hospital Costa del Sol
Marbella, , Spain
Site Status
RECRUITING
Kantonsspital Winterthur
Zurich, Winterthur, Switzerland
Site Status
RECRUITING
Clarunis St. Clara Spital
Basel, , Switzerland
Site Status
NOT_YET_RECRUITING
Universitätsspital Bern, Inselspital
Bern, , Switzerland
Site Status
RECRUITING
University Hospitals of Geneva
Geneva, , Switzerland
Site Status
RECRUITING
University Hospital of Lausanne CHUV
Lausanne, , Switzerland
Site Status
RECRUITING
Kantonsspital Basel Land
Liestal, , Switzerland
Site Status
NOT_YET_RECRUITING
Spital Männedorf
Männedorf, , Switzerland
Site Status
RECRUITING
Ospedale Regionale di Mendrisio
Mendrisio, , Switzerland
Site Status
RECRUITING
HOCH Kantonsspital St. Gallen
Sankt Gallen, , Switzerland
Site Status
RECRUITING
Spital Limmattal
Schlieren, , Switzerland
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Belgium
France
Greece
Spain
Switzerland
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Roswitha Koeberle-Wührer, MD
Role: primary
Tobias Zingg, MD
Role: primary
Role: backup
Christine Glauser, MD
Role: primary
Robert Mechera, MD
Role: primary
Role: backup
Giuseppe Peloni, MD
Role: primary
Role: backup
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BASEC Nr 2024-01766
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Classic Total Thyroidectomy With or Without Drains
NCT00691990
COMPLETED
NA
ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy
NCT02973802
COMPLETED
PHASE1
Prevalence and Predictors of Incidental Thyroid Carcinoma in Patients With Graves' Disease Undergoing Thyroidectomy.
NCT07059507
RECRUITING
Remission Induction and Sustenance in Graves' Disease 2
NCT00796913
COMPLETED
NA
A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy
NCT04776993
RECRUITING
PHASE3
Immediate Postoperative Course of Patients With Mini Video Assisted Total Thyroidectomy (miVAT) Versus Classic Total Thyroidectomy (cTT)
NCT00692835
COMPLETED
NA
Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism
NCT04932135
COMPLETED
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604
RECRUITING
PHASE2
Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration
NCT00196729
COMPLETED
PHASE3
Heart Rate Monitoring by Wearable Devices in Graves' Disease
NCT04333342
UNKNOWN
NA
Late Postoperative Course of Patients With Mini Video Assisted Thyroidectomy (miVAT) Versus Classic Thyroidectomy (T)
NCT00693147
COMPLETED
NA
Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients
NCT03276988
COMPLETED
PHASE1/PHASE2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT07018323
RECRUITING
PHASE2
Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease
NCT07261345
RECRUITING
EARLY_PHASE1
Coexisting Thyroid Disease and Hyperparathyroidism
NCT01306916
COMPLETED
A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours
NCT01736163
COMPLETED
Methimazole in Graves' Disease - Comparing the Computer-aided Treatment DigiThy Versus Usual Care
NCT06327828
NOT_YET_RECRUITING
NA
Prospective Evaluation of OptiThyDose
NCT06864351
RECRUITING
NA
A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China
NCT07040306
RECRUITING
Antithyroid Drugs During Radioiodine Therapy
NCT00150137
COMPLETED
PHASE4
Low-dose Radioiodine Ablation in Graves' Disease
NCT03110835
COMPLETED
Perioperative Parathormone Measurement and Sodium Bicarbonate Infusion Test After Total Thyroidectomy
NCT00793689
COMPLETED
Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism
NCT01039818
COMPLETED
PHASE3
Early Levothyroxine Post Radioactive Iodine
NCT01950260
COMPLETED
PHASE2/PHASE3
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
NCT05907668
COMPLETED
PHASE2